newsfilter
← Latest News
Business Wire·

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

-- Targeted Complement Activating Therapy™ Represents Next-Generation, Broadly Applicable Antimicrobial Therapeutics – Omeros Corporation (NASDAQ:OMER) today announced that the first public presentation of its